Galapagos NV

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:37:06 2024-05-13 am EDT			After market 12:31:20 pm
26.56 ^EUR	-0.38%		26.49	-0.26%

May. 03	Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
May. 02	Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Van Herk Investments Provides Nomination Notice to Galapagos NV

November 02, 2021 at 04:44 pm EDT

On November 2, 2021, Van Herk Investments B.V. announced that it has provided notice to Galapagos NV of its intent to nominate Dharminder Chahal for election to the Company?s board of directors.

Latest news about Galapagos NV

Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024	May. 03
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	Apr. 08	CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	Mar. 28	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	Mar. 28	MT
Galapagos NV Announces Board Changes	Mar. 27	CI
Galapagos to Seek Acquisitions	Feb. 23	CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024	Feb. 23
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors	Feb. 21	CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024	Feb. 15	CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma	Feb. 01	MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding	Jan. 30	CI
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV.	Jan. 30	CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S	Jan. 05	CI
Galapagos Partners with Thermo Fisher for Manufacturing in US	Jan. 05	MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network	Jan. 04	MT
Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug	Jan. 04	DJ
Galapagos, BridGene Biosciences Partner to Develop New Medicines for Oncology Targets	Jan. 04	MT
Galapagos to Collaborate With BridGene to Discover, Develop New Medicines for Oncology Targets	Jan. 03	MT
BridGene Biosciences, Inc. Announces Strategic Collaboration and Licensing Agreement with Galapagos NV	Jan. 03	CI
Global markets live: HSBC, Baidu, Exxon Mobil, Geely, Tesla...	Jan. 02
Galapagos to Divest Jyseleca Business in Biotechnology Shift	Jan. 02	MT
Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos	Jan. 02	CI
Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301	Dec. 21	CI

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.66 EUR

Average target price

37.03 EUR

Spread / Average Target

+38.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GALAPAGOS NV	-28.20%	1.89B
MODERNA, INC.	+23.65%	44.96B
IQVIA HOLDINGS INC.	+0.35%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+10.82%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.11%	19.03B
BIO-TECHNE CORPORATION	+6.34%	12.75B
MEDPACE HOLDINGS, INC.	+29.23%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.42%	11.75B

Other Biotechnology & Medical Research

Galapagos NV

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Van Herk Investments Provides Nomination Notice to Galapagos NV

Latest news about Galapagos NV

Chart Galapagos NV

Company Profile

Income Statement Evolution

Ratings for Galapagos NV

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research